Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nintedanib in Molecularly Selected Advanced NSCLC
NCT02299141Phase 2Completed
- Sponsor
- Washington University School of Medicine
- Start
- May 2015
- Primary completion
- Jan 2020
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of nintedanib in non-small cell lung cancer (NSCLC), sponsored by Washington University School of Medicine. Started May 2015; status: completed.
02
Drugs
nintedanib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02299141.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02299141.